Evidence map›Paper›PMID 36251051›Full record

ArticleHeart and vessels2023

Impact of the COVID-19 pandemic on the hospitalizations, time course, presenting symptoms, and mid-term outcomes in patients with myocardial infarctions in a Japanese multi-center registry.

Riku Arai, Murata Nobuhiro, Keisuke Kojima, Korehito Iida, Daisuke Kitano, Daisuke Fukamachi, Yoji Watanabe, Michiaki Matsumoto, Naoya Matsumoto, Shu Hirata and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heart and vessels, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Riku AraiDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Murata NobuhiroDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Keisuke KojimaDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Korehito IidaDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Daisuke KitanoDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Daisuke FukamachiDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Yoji WatanabeDepartment of Cardiology, Nihon University Hospital, Tokyo, Japan.
Michiaki MatsumotoDepartment of Cardiology, Nihon University Hospital, Tokyo, Japan.
Naoya MatsumotoDepartment of Cardiology, Nihon University Hospital, Tokyo, Japan.
Shu HirataTokyo Rinkai Hospital, Tokyo, Japan.
Kazumiki NomotoTokyo Rinkai Hospital, Tokyo, Japan.
Yusuke SasaKawaguchi Municipal Medical Center, Saitama, Japan.
Eizo TachibanaKawaguchi Municipal Medical Center, Saitama, Japan.
Masaru AraiKasukabe Municipal Hospital, Saitama, Japan.
Ken ArimaKasukabe Municipal Hospital, Saitama, Japan.
Hironori HarutaTMG Asaka Medical Center, Saitama, Japan.
Yasuo OkumuraDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan. yasuwo128@hotmail.co.jp.ORCID http://orcid.org/0000-0002-2960-4241
Nihon University · JPNoguchi Hospital · JPSaitama Municipal Hospital · JPTokyo Rinkai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate the impact of the coronavirus disease 2019 (COVID-19) pandemic on myocardial infarctions (MIs), consecutive MI patients were retrospectively reviewed in a multi-center registry. The patient characteristics and 180-day mortality for both ST-segment elevation myocardial infarctions (STEMIs) and non-STEMIs (NSTEMIs) in the after-pandemic period (7 April 2020-6 April 2021) were compared to the pre-pandemic period (7 April 2019-6 April 2020). Inpatients with MIs, STEMIs, and NSTEMIs decreased by 9.5%, 12.5%, and 4.1% in the after-pandemic period. The type of the presenting symptoms (as classified as typical symptoms, atypical symptoms, and out-of-hospital cardiac arrests [OHCAs]) did not differ between the two time periods for both STEMIs and NSTEMIs, while the rate of OHCAs was numerically higher in the after-pandemic period for the STEMIs (12.1% vs. 8.0%, p = 0.30). The symptom-to-admission time (STAT) did not differ between the two time periods for both STEMIs and NSTEMIs, but the door-to-balloon time (DTBT) for STEMIs was significantly longer in the after-pandemic period (83.0 [67.0-100.7] min vs. 70.0 [59.0-88.7] min, p = 0.004). The 180-day mortality did not significantly differ between the two time periods for both STEMIs (15.9% vs. 11.4%, p = 0.14) and NSTEMIs (9.9% vs. 8.0%, p = 0.59). In conclusion, hospitalizations for MIs decreased after the COVID-19 pandemic. Although the DTBTs were significantly longer in the after-pandemic period, the mid-term outcomes for MIs were preserved.

Indexed as

COVID-19Myocardial InfarctionST Elevation Myocardial InfarctionEast Asian PeopleHospitalizationHumansPandemicsRegistriesRetrospective StudiesCOVID-19 pandemicMyocardial infarctionPresenting symptom

Identifiers

PMID36251051
PMCPMC9575639
OpenAlexW4306410022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.